Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT02235519
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 300 participants
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Registry
-
NCT02235519
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Unknown status
Technical summary
Registry record NCT02235519. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
- Condition
- Hypertension
- Condition
- Obesity
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Azilsartan 40 mg.
- Intervention (Drug)
- Azilsartan 80 mg
- Lead sponsor
- Hospital General de México Dr. Eduardo Liceaga
Record details
- Record id
cardio:ct-nct02235519- Content hash
c9fa6d1f47e4d470b10f474105c25023f0694804cbaa9ebc926521efbded8c22